IT8247635A0 - Complessi di ciclodestrine e glicosidi cardiaci per uso terapeutico e procedimento di preparazione - Google Patents

Complessi di ciclodestrine e glicosidi cardiaci per uso terapeutico e procedimento di preparazione

Info

Publication number
IT8247635A0
IT8247635A0 IT8247635A IT4763582A IT8247635A0 IT 8247635 A0 IT8247635 A0 IT 8247635A0 IT 8247635 A IT8247635 A IT 8247635A IT 4763582 A IT4763582 A IT 4763582A IT 8247635 A0 IT8247635 A0 IT 8247635A0
Authority
IT
Italy
Prior art keywords
cyclodextrins
complexes
therapeutic use
preparation procedure
cardiac glycosides
Prior art date
Application number
IT8247635A
Other languages
English (en)
Other versions
IT1147806B (it
Inventor
Harry Phillip Jones
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of IT8247635A0 publication Critical patent/IT8247635A0/it
Application granted granted Critical
Publication of IT1147806B publication Critical patent/IT1147806B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IT47635/82A 1981-01-23 1982-01-22 Complessi di ciclodestrine e glicosidi cardiaci per uso terapeutico e procedimento di preparazione IT1147806B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8102124 1981-01-23

Publications (2)

Publication Number Publication Date
IT8247635A0 true IT8247635A0 (it) 1982-01-22
IT1147806B IT1147806B (it) 1986-11-26

Family

ID=10519177

Family Applications (1)

Application Number Title Priority Date Filing Date
IT47635/82A IT1147806B (it) 1981-01-23 1982-01-22 Complessi di ciclodestrine e glicosidi cardiaci per uso terapeutico e procedimento di preparazione

Country Status (10)

Country Link
US (1) US4555504A (it)
EP (1) EP0056995B1 (it)
JP (1) JPS57182301A (it)
AU (1) AU558787B2 (it)
CA (1) CA1222742A (it)
DE (1) DE3270055D1 (it)
IE (1) IE52500B1 (it)
IT (1) IT1147806B (it)
NZ (1) NZ199543A (it)
ZA (1) ZA82447B (it)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
US4675395A (en) * 1984-03-14 1987-06-23 Seiwa Technological Laboratories Limited Cyclodextrin inclusion compound and process for its preparation
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4764601A (en) * 1985-10-18 1988-08-16 The Ohio State University Research Foundation Composition for assaying cardiac glycosides from serum or plasma
JPS6333341A (ja) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
US4798804A (en) * 1987-02-05 1989-01-17 Syntex (U.S.A.) Inc. Serum pretreatment in digoxin immunoassay
HU201685B (en) * 1987-04-23 1990-12-28 Chinoin Gyogyszer Es Vegyeszet For producing pharmaceutical compositions for inhalation and compositions for scenting air containing volatile active component in cyclodextrine inclusion, and air-scenting composition
US4840679A (en) * 1987-07-08 1989-06-20 American Maize-Products Company Purification and separation of branched beta-cyclodextrins
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
YU45837B (sh) * 1988-01-18 1992-07-20 LEK TOVARNA FARMACEVTSKIH IN KEMIČKIH IZDELKOV d.d. Postopek za pripravo novega inkluzijskega kompleksa nikardipina oz. njegovega hidroklorida z beta-ciklodekstrinom
US5223295A (en) * 1988-01-22 1993-06-29 Asterol International Process for the elimination of steroid compounds contained in substance of biological origin
WO1990001320A1 (en) * 1988-08-15 1990-02-22 American Maize-Products Company Water soluble branched beta cyclodextrin steroid complex
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5703088A (en) * 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5574041A (en) * 1990-03-16 1996-11-12 Beth Israel Hospital Association Use of spiperone derivatives as immunosuppressant agents
ES2121779T3 (es) * 1990-03-16 1998-12-16 Beth Israel Hospital Utilizacion de espiperona como agente inmunosupresor y antiinflamatorio.
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5693645A (en) * 1992-12-23 1997-12-02 Beth Israel Deaconess Medical Center, Inc. Use of spiperone or spiperone derivatives as immunosuppressant agents
US5362860A (en) * 1993-02-01 1994-11-08 Warner-Lambert Company Neutral stabilization complex for CI-979 HCl, a cognition activator
US5658390A (en) * 1994-06-29 1997-08-19 American Maize-Products Company Purification of beta cyclodextrin
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) * 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
WO2004087121A2 (en) * 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060205679A1 (en) * 2004-10-22 2006-09-14 Azaya Therapeutics, Inc. Topical and oral formulations of cardiac glycosides for treating skin diseases
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
WO2010017480A1 (en) * 2008-08-07 2010-02-11 Centrose, Llc Glycoside compounds and pharmaceutical compositions thereof
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
BR112012020316A2 (pt) * 2010-02-08 2015-09-01 Coca Cola Co Glicosídeo(s) de terpeno com solubidade intensificada
WO2012163546A1 (en) * 2011-06-03 2012-12-06 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
CN115154619B (zh) 2016-02-04 2025-11-28 西泽普研究与发展有限责任公司 受控释放和层状的环糊精包合物媒介物
EP4653002A3 (en) 2020-03-23 2026-02-25 Czap Research And Development, LLC Oral terpene cyclodextrin inclusion complex vehicles
CN116236442B (zh) * 2023-03-20 2025-05-02 湖北民康药业集团有限公司 地高辛注射液及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE513723A (it) * 1900-01-01
DE895769C (de) * 1951-08-26 1953-11-05 Knoll Ag Verfahren zur Herstellung von Einschlussverbindungen physiologisch wirksamer organischer Verbindungen
US3541077A (en) * 1968-05-31 1970-11-17 Cpc International Inc Method of preparing pure alpha-cyclodextrin
JPS50160416A (it) * 1974-06-24 1975-12-25
JPS51118817A (en) * 1975-04-08 1976-10-19 Nippon Shinyaku Co Ltd A process for preparing absorbable steroid glycoside pharmaceutical
JPS5762297A (en) * 1980-10-01 1982-04-15 Mitsubishi Yuka Yakuhin Kk Digitalis cardiac glycoside-cyclodextrin inclusion compound

Also Published As

Publication number Publication date
EP0056995B1 (en) 1986-03-26
DE3270055D1 (en) 1986-04-30
CA1222742A (en) 1987-06-09
IE820136L (en) 1982-07-23
US4555504A (en) 1985-11-26
IE52500B1 (en) 1987-11-25
AU558787B2 (en) 1987-02-12
IT1147806B (it) 1986-11-26
EP0056995A1 (en) 1982-08-04
ZA82447B (en) 1983-09-28
AU7973482A (en) 1982-07-29
JPS57182301A (en) 1982-11-10
NZ199543A (en) 1985-04-30

Similar Documents

Publication Publication Date Title
IT1147806B (it) Complessi di ciclodestrine e glicosidi cardiaci per uso terapeutico e procedimento di preparazione
PT80292B (pt) Preparacao de factor viii humano funcional
ES530811A0 (es) Procedimiento de desapresto-blanqueo simultaneo de tejidos
NO872966L (no) Fremgangsmaate for fremstilling av granulocyttstimulerende preparater.
KR880701554A (ko) 스테로이드제 함유 외용 첩부제
IT1163001B (it) Procedimento per la preparazione di 4' epidaunorubicina 3', 4' diepidaunorubicina e corrispondenti analoghi della doxorubicina
IT1153294B (it) Composizione di antralina migliorata e suo uso nel trattamento di malattie della pelle
NO872551D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
DK565089D0 (da) Hudpraeparater
IT1200085B (it) Procedimento per la preparazione di xantoni e di tioxantoni
NZ193078A (en) Derivatives of 9-aminoalkyl-flyorene medicinal preparations
DK489587A (da) Medicinsk hudpraeparat
NO167664C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive castanosperminestere og glycosider.
IT1170861B (it) Ester di mercaptoacil-carnitine procedimento per la loro preparazione e loro uso terapeutico
IT7850483A0 (it) Combinazione di farmaci avente azione antitrombotica e procedimento per la sua preparazione
NO874200D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
IT1156478B (it) Procedimento per la preparazione di acril e metacril ammidi
IT1130076B (it) Procedimento per la preparazione di solfossidi di penicellina
IT1170862B (it) Mercaptoacil-carnitine procedimento per la loro preparazione e loro uso terapeutico
NO875359L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO873423D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
NO872233D0 (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater
IT1223408B (it) Procedimento per la preparazione di monosialoganglioside
IT1151104B (it) Impiego terapeutico di derivati (1-cinnamoil oppure 1-fenetil-carbonil)piperazinici
IT1217177B (it) Palmitoil-fruttosio-1,6-difosfato,suo uso terapeutico e relativi metodi di preparazione